Low-Density Lipoprotein Reduction and Cancer. Not Definitive But Provocative**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 5, 2007, Pages 421-422

  DeMaria, Anthony N ^a   Ben Yehuda, Ori ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TIROFIBAN;

CANCER; CLINICAL TRIAL; EDITORIAL; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHABDOMYOLYSIS;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER DISEASES; NEOPLASMS; RESEARCH DESIGN; RHABDOMYOLYSIS;

EID: 34447635241     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.06.003     Document Type: Editorial

References (2)

1. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
2. LaRosa J.C. Means and ends of statins and low-density lipoprotein cholesterol lowering. J Am Coll Cardiol 50 (2007) 419-420